Discover
PALI
Palisade Bio, Inc.
2.10
4 x 1.96
9 x 2.10
bid
ask
-
0.01
0.47%
1 @ 04:00 PM
2.05 -0.05 (2.25%)
| Ytd | -10.64% | |
| 1y | 165.82% |
2.03
day range
2.10
0.53
52 week range
2.86
| Open | 2.10 | Prev Close | 2.11 | Low | 2.03 | High | 2.10 | Mkt Cap | 364.52M |
| Vol | 1.26M | Avg Vol | 3.15M | EPS | -1.05 | P/E | -2.00 | Forward P/E | -0.19 |
| Beta | 1.52 | Short Ratio | 0.29 | Inst. Own | 3.58% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 1.94 | 200-d Avg | 1.93 | 1yr Est | 30.33 |
PALI News
benzinga.com
Palisade Bio Q2 EPS $(0.05), Inline, Sales $500.000K
Palisade Bio (NASDAQ:PALI) reported quarterly losses of $(0.05) per share which met the analyst cons
globenewswire.com
Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of P
Advancing a potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug spec
benzinga.com
This Signet Jewelers Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thurs
Top analysts change outlook on top names. See all changes and ratings on our analyst ratings page. C
benzinga.com
Oppenheimer Initiates Coverage On Palisade Bio with Outperform Rating, Announces Price Target of $8
Oppenheimer analyst Leland Gershell initiates coverage on Palisade Bio (NASDAQ:PALI) with a Outpe